Companies · RMD
ResMed
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Oct 30, 2026
ResMed Q1 FY2027: Sleep and Breathing Health grows 8%, MatrixCare divestiture closes, Noctrix acquisition adds neurology exposure
ResMed's Sleep and Breathing Health segment delivered 8% revenue growth in Q1 FY2027, driven by broad-based demand in devices and masks across both Americas and Rest of World, with masks and other growing 10% globally. The MatrixCare divestiture closed September 1, 2026, generating a $62 million gain and enabling an accelerated $450 million share repurchase; the Residential Care Software segment declined 7% as a direct result of that disposition. The acquisition of Noctrix — disclosed only in passing in SG&A commentary — signals a new neurological therapy adjacency, while inflationary pressure on electronic components and expanding supply chain sites introduce gross margin volatility heading into the remainder of FY2027.
Tone: bullishRevenue
$5.7B
RMD 10-K · FY 2026
Employees
11,370
Revenue growth YoY
+10%
Founded
1989
Profile
RMD 10-K Item 1 · Aug 13, 2026ResMed is a global leader in digital health and cloud-connected medical devices, focused on sleep apnea, chronic respiratory disease, and home-based care. The company designs AI-powered devices, diagnostic tools, mask systems, and cloud software platforms that enable remote patient monitoring and therapy management. It also provides residential care software to HME, home health, hospice, skilled nursing, and senior living providers.
Read filing description ↓ Collapse description ↑
We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems. Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA. Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients' long-term adherence to and satisfaction with their therapy. We also provide management software that assists providers to operate more effectively and efficiently across various residential care settings. We employ approximately 11,370 people and sell our products in more than 140 countries through a combination of wholly owned subsidiaries and independent distributors.
Primary products
- AirSense 11 AutoSet
- AirSense 11 CPAP
- AirSense 10 AutoSet
- AirCurve 11 VAuto
- AirCurve 11 ASV
- AirCurve 10 VAuto
Business segments
End markets
Geographies
Named competitors
“We are the leader in developing smaller, quieter, more comfortable and more connected products.” Competitive position, as stated in the filing
Revenue commentary · FY 2026
Net revenue increased $507 million, or 10% (8% on a constant currency basis), driven by growth in both Sleep and Breathing Health and Residential Care Software segments.
The rest of RMD is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.